No insider open-market trades in 90 days (SEC Form 4). Congress: no trades disclosed in 180 days.
Analyst target and ratings are on paid plans
See the 12-month consensus target and the buy/hold/sell rating split.
Unlock the full resultsEach bar is 100% of that source’s money. The notch marks an even split.
Lean is the direction of the latest moves. Descriptive, not advice.
Buys/Adds (1)
Qube Research
$214.6M
added
Sells/Trims (2)
Balyasny
$73.9M
trimmed
D.E. Shaw
$64.6M
trimmed
Buys (2)
Boudreaux Gail
$1.0M
bought
Peru Ramiro G
$366K
bought
Sells (1)
Penczek Ronald W
$149K
sold
No tracked top-trader positions in ELV as of Oct 21, 14:10 UTC.
Hyperliquid positioning - not every stock is covered
Last report
Oct 21, 2026
Financial period
3Q 2026
Adjusted EPS
Company release
Revenue
Company release
Company GAAP EPS $6.27
EPS comparison unavailable.
| Period ending | Reported | EPS / estimate | EPS surprise | Revenue / income | Surprise |
|---|---|---|---|---|---|
| Jun 30, 2026 | Jul 15, 2026 | $7.45 / $6.21Yahoo Finance | +19.99% beat | $49.80B No estimate | Unavailable |
| Mar 31, 2026 | Apr 22, 2026 | $12.58 / $10.81Yahoo Finance | +16.36% beat | $50.18B No estimate | Unavailable |
| Dec 31, 2025 | Jan 28, 2026 | $3.33 / $3.09Yahoo Finance | +7.65% beat | $49.75B No estimate | Unavailable |
| Sep 30, 2025 | Oct 21, 2025 | $6.03 / $4.94Yahoo Finance | +22.01% beat | $50.71B No estimate | Unavailable |
| Jun 30, 2025 | Jul 17, 2025 | $8.84 / $8.92Alpha Vantage | -0.90% in line | $49.78B No estimate | Unavailable |
| Mar 31, 2025 | Apr 22, 2025 | $11.97 / $11.48Alpha Vantage | +4.27% beat | $48.89B No estimate | Unavailable |
| Dec 31, 2024 | Jan 23, 2025 | $3.84 / $3.85Alpha Vantage | -0.26% in line | $45.44B No estimate | Unavailable |
| Sep 30, 2024 | Oct 17, 2024 | $8.37 / $9.65Alpha Vantage | -13.26% miss | $45.15B No estimate | Unavailable |
EPS uses Yahoo Finance where available, then Alpha Vantage or verified release comparisons. Revenue and income use company releases, SEC filings, Alpha Vantage or Yahoo Finance. Non-USD revenue carries its currency code. Comparisons require a paired release estimate.
| USD | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|
| What came in | ||||
| Revenue | $50.71B | $49.75B | $50.18B | $50.47B |
| Cost of what it sold | $38.14B | $38.06B | $41.08B | $5.49B |
| Gross profit | $12.57B | $11.68B | $9.10B | $44.98B |
| What it spent | ||||
| Sales and admin | — | — | $6.33B | — |
| Other operating costs | $10.81B | $11.10B | $112.0M | $42.92B |
| Total operating expenses | $10.81B | $11.10B | $6.44B | $42.92B |
| What was left | ||||
| Operating profit | $1.76B | $581.0M | $2.66B | $2.06B |
| Interest on debt | $351.0M | $366.0M | $357.0M | $56.0M |
| Profit before tax | $1.41B | $215.0M | $2.30B | $1.94B |
| Tax | $219.0M | -$331.0M | $544.0M | $483.0M |
| Net profit | $1.19B | $547.0M | $1.76B | $1.46B |
| EBITDA | $2.14B | $987.0M | $3.02B | $2.36B |
This stock is in a strong uptrend, and looks overbought after a fast run-up.
Trend
Strong uptrend
85 / 100
RSI 14
20D volatility
52-week range
20D support
20D resistance
Returns
Price vs moving averages
Volume pace
Coverage is bullish
Is Elevance Health, Inc. (ELV) Outperforming Other Medical Stocks This Year?
BullishOct 19Guggenheim raises target for Elevance Health stock from USD 455 to USD 460
Leans bullishOct 19Centene Corp. stock closes at USD 69.16 near its daily high USD 71.06
NeutralOct 1717 analysts set a USD 202.44 target for Molina Healthcare stock
NeutralOct 17Elevance Health stock: Guggenheim lifts target to USD 460 for Elevance Health stock
BullishOct 16Unveiling Elevance Health (ELV) Q3 Outlook: Wall Street Estimates for Key Metrics
NeutralOct 16Elevance Health sets October 21 results: stock trades at EUR 381.50
Leans bullishOct 16Elevance Q3 Earnings Preview: Will Lower Premiums Weigh on Results?
Leans bearishOct 15